GLPwatch
[GLP-1 receptor agonists : impact on diabetic kidney disease].
Rev Med Suisse · 2024
Last updated 2026-05-28A study called the FLOW trial found that the GLP-1 drug semaglutide reduced kidney-related events in people with type 2 diabetes and kidney disease compared to a placebo. The trial specifically looked at semaglutide’s impact on kidney outcomes as its main focus.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2024 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
In addition to optimal glycemic control and management of other factors aggravating the pathology (hypertension, dyslipidemia, -obesity), the cornerstone of treatment of diabetic kidney disease (DKD) includes blockers of the renin-angiotensin system, sodium-glucose cotransporter 2 inhibitors or nonsteroidal antagonists of the mineralocorticoid receptor (finerenone). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended in the treatment of high-risk patients with type 2 diabetes (T2DM) to reduce cardiovascular (CV) risk. Data from CV studies indicate a nephroprotective effect of certain GLP-1 RAs in T2DM patients with DKD. The FLOW study published in May 2024, analyzing the impact of semaglutide vs placebo on renal events as primary outcome, confirms this renal protection of GLP-1 RAs.
Verbatim abstract via PubMed 39219391 ↗